In order to meet the needs of rapid development of company, company plans to build a new pharmaceutical production base in zhihuiyuan, beicheng, gongshu district, with a total area of about 24 Acre-feet. Upon completion of the base, it will reach: the annual output of class III medical device manufacturing workshop is 10 million pieces of sodium hyaluronate gel for medical use (cross-linking), and the annual output of class I medical device manufacturing workshop is 10 million pieces of cold compress/tablet for medical use. Meanwhile, the production workshop of class II medical devices is reserved for the production of balloon and wound dressing. The base also includes medical device r&d pilot plant, drug production plant (reserved), quality control center, logistics center and so on. At present, land acquisition, preliminary design and key equipment selection have been completed, and construction is scheduled to be completed by the end of 2021.
Secondly, in order to fundamentally solve the problem of core raw material supply guarantee, establish complete industrial chain, the company controlling shareholder investment in new district of hangzhou qiantang river area construction of sodium hyaluronate raw materials production base, with a total area of about 85 mu, mainly for medical grade food grade sodium hyaluronate and cosmetics raw materials and cosmetics (hyaluronic acid mask and concentrate, etc.) of production, planning with an annual output of 500 kg of medical grade sodium hyaluronate raw materials, cosmetics, food grade sodium hyaluronate 120 tons of raw materials, related medical sodium hyaluronate gel preparation for the company product supply high quality raw material for sodium hyaluronate.
R & D Pilot Plant
Quality Control Center